Practice Point®: Rare Diseases

In this podcast, Dr. Hirbe dives into RAS signaling Axis, rationale for MEK inhibition, and a high level overview of clinical evidence.

In this module, Dr Hirbe reviews clinical case scenarios, key takeaways, and referral framework.

Visit the link in our bio to earn FREE AMA, ABS, or ANCC credit!

In this module, Dr. Hirbe dives into RAS signaling Axis, rationale for MEK inhibition, and a high level overview of clinical evidence.

Visit the link in our bio to earn FREE AMA, ABS, or ANCC credit!

In this module, Dr. Hirbe provides an overview of NF1-PN, how to recognize NF1-PN, and diagnosing and monitoring patients with NF1-PN.

Visit the link in our bio to earn FREE AMA, ABS, or ANCC credit!

Using a realistic patient case, this final episode demonstrates how expert clinicians evaluate, diagnose, and manage a patient with suspected adult HLH in real time. Faculty discuss the interpretation of evolving clinical findings, biomarkers, and imaging, while highlighting common diagnostic pitfalls, treatment escalation strategies, and the importance of identifying the underlying trigger. The case illustrates how multidisciplinary decision-making and early intervention can improve outcomes in this complex and rapidly evolving syndrome.

Launch/Release Date: July 23, 2026

Activity Expiration Date: June 30, 2027

Faculty

Sarah Nikiforow, MD, PhD

Assistant Professor, Stem Cell Transplantation

Medical Director, DFCI Cell Manipulation Core Facility

Technical Director, DFCI Immune Effector Cell Therapy Program

Dana-Farber Cancer Institute

Daniella Schwartz, MD

Assistant Professor

Division of Rheumatology and Clinical Immunology

Departments of Medicine and Immunology

Co-Director, Autoinflammatory Center of Excellence

Co-Director, Pittsburgh Immunogenetics Discovery Center

University of Pittsburgh Medical Center

This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

Successful management of adult HLH requires simultaneous control of hyperinflammation and identification of the underlying trigger. In this episode, faculty review practical treatment approaches, including corticosteroids, targeted immunomodulatory therapies, and selective use of etoposide-based regimens, while highlighting the growing role of pathway-directed therapies. The discussion emphasizes multidisciplinary care, ongoing reassessment, and individualized treatment decisions based on disease biology and clinical response.

Launch/Release Date: July 23, 2026

Activity Expiration Date: June 30, 2027

Faculty

Sarah Nikiforow, MD, PhD

Assistant Professor, Stem Cell Transplantation

Medical Director, DFCI Cell Manipulation Core Facility

Technical Director, DFCI Immune Effector Cell Therapy Program

Dana-Farber Cancer Institute

Daniella Schwartz, MD

Assistant Professor

Division of Rheumatology and Clinical Immunology

Departments of Medicine and Immunology

Co-Director, Autoinflammatory Center of Excellence

Co-Director, Pittsburgh Immunogenetics Discovery Center

University of Pittsburgh Medical Center

This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

Early recognition is critical to improving outcomes in adult HLH. This episode explores the clinical features, common triggers, and laboratory abnormalities that should raise suspicion for HLH, while reviewing the strengths and limitations of current diagnostic tools, including the HLH-2004 criteria, HScore, and emerging biomarker strategies. Faculty also discuss how trends in ferritin and immune biomarkers can support earlier diagnosis and more informed risk stratification.

Launch/Release Date: July 23, 2026

Activity Expiration Date: June 30, 2027

Faculty

Sarah Nikiforow, MD, PhD

Assistant Professor, Stem Cell Transplantation

Medical Director, DFCI Cell Manipulation Core Facility

Technical Director, DFCI Immune Effector Cell Therapy Program

Dana-Farber Cancer Institute

Daniella Schwartz, MD

Assistant Professor

Division of Rheumatology and Clinical Immunology

Departments of Medicine and Immunology

Co-Director, Autoinflammatory Center of Excellence

Co-Director, Pittsburgh Immunogenetics Discovery Center

University of Pittsburgh Medical Center

This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

Adult hemophagocytic lymphohistiocytosis (HLH) is a rapidly progressive hyperinflammatory syndrome that often presents with nonspecific features, making early diagnosis challenging. In this introductory episode, expert faculty explain the underlying immunobiology of adult HLH, distinguish primary from secondary disease, and explore why HLH should be viewed as a syndrome rather than a single disease entity. The discussion establishes the clinical framework needed to recognize patients at risk and prepares learners for the practical diagnostic and management strategies covered throughout the series.

Launch/Release Date: July 23, 2026

Activity Expiration Date: June 30, 2027

Faculty

Sarah Nikiforow, MD, PhD

Assistant Professor, Stem Cell Transplantation

Medical Director, DFCI Cell Manipulation Core Facility

Technical Director, DFCI Immune Effector Cell Therapy Program

Dana-Farber Cancer Institute

Daniella Schwartz, MD

Assistant Professor

Division of Rheumatology and Clinical Immunology

Departments of Medicine and Immunology

Co-Director, Autoinflammatory Center of Excellence

Co-Director, Pittsburgh Immunogenetics Discovery Center

University of Pittsburgh Medical Center

This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

Managing uncontrolled gout isn’t always straightforward—especially when flares persist, comorbidities complicate care, or standard therapies fall short. As our understanding of gout expands beyond just elevated uric acid, clinicians are being asked to think differently, integrating immune pathways, real-world evidence, and emerging treatments into everyday practice.

From Refractory to Resolved: Rethinking Uncontrolled Gout in 2026, this CME-accredited podcast explores how to approach these complex cases with greater clarity and confidence. Featuring expert insights and the latest clinical evidence, each episode dives into practical strategies across the continuum of gout care.

Listeners will hear discussions on advances in uricase-based therapies, selective URAT1 inhibitors, and inflammation-targeted treatments, along with key considerations around safety, sequencing, and collaborative care. Through real-world examples and focused conversations, this series equips clinicians with actionable tools to personalize treatment, address therapeutic challenges, and improve long-term outcomes for patients living with uncontrolled gout.

Launch Date/Release: June 12, 2026

Expiration Date: May 31, 2027

FACULTY

Robert Terkeltaub, MD

Professor Emeritus of Medicine,

University of California, San Diego

This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

Managing uncontrolled gout isn’t always straightforward—especially when flares persist, comorbidities complicate care, or standard therapies fall short. As our understanding of gout expands beyond just elevated uric acid, clinicians are being asked to think differently, integrating immune pathways, real-world evidence, and emerging treatments into everyday practice.

From Refractory to Resolved: Rethinking Uncontrolled Gout in 2026, this CME-accredited podcast explores how to approach these complex cases with greater clarity and confidence. Featuring expert insights and the latest clinical evidence, each episode dives into practical strategies across the continuum of gout care.

Listeners will hear discussions on advances in uricase-based therapies, selective URAT1 inhibitors, and inflammation-targeted treatments, along with key considerations around safety, sequencing, and collaborative care. Through real-world examples and focused conversations, this series equips clinicians with actionable tools to personalize treatment, address therapeutic challenges, and improve long-term outcomes for patients living with uncontrolled gout.

Launch Date/Release: June 12, 2026

Expiration Date: May 31, 2027

FACULTY

Robert Terkeltaub, MD

Professor Emeritus of Medicine,

University of California, San Diego

This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.